For laboratory research use only. This page summarizes public scientific literature. It is not medical advice and does not describe or endorse human, clinical, or veterinary use.
Chemistry & identity
| CAS Number | 2381089-83-2 |
|---|---|
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | 4731 g/mol |
| Residue Count | 39 |
| PubChem CID | 171390338 |
Peptide sequence
YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS
Research context
Sequence transcribed from the three-letter sequence listed on the PubChem "Retatrutide sodium" record: Tyr-(Aib)-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(alpha-Me-Leu)-Leu-Asp-Lys-(diacid-C20-gamma-Glu-(AEEA)-Lys)-Ala-Gln-(Aib)-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2. X = Aib (2, 20) and alpha-methyl-Leu (13).
Selected research references
Published peer-reviewed literature on RT-3 (GLP-3). Provided for research-context purposes only; CC Peptides does not make claims about outcomes in humans.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
RT-3 (GLP-3) for laboratory research
CC Peptides supplies RT-3 (GLP-3) as a lyophilized reference material with a third-party COA. Ships from California.
View product page →